Table 5.
Univariate and multiple proportional hazards regression analyses for patients with thymic carcinoma (n=34)
| Univariate | Multiple Regression | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Comparison* (N) | P (Log-rank) | P (Trend) | Hazard Ratio (HR) | 95% CI | Hazard Ratio (HR) | 95% CI |
| Age | 0.17 | 0.31 | |||||
| <40 (6) vs. 40–51 (6) | 0.15 | 0.02, 1.29 | |||||
| <40 vs. 51–62 (9) | 0.29 | 0.07, 1.13 | |||||
| <40 vs. >62 (13) | 0.39 | 0.11, 1.38 | |||||
| Sex | Female (13) vs. Male (21) | 0.32 | 1.72 | 0.59, 5.04 | 2.32 | 0.74, 7.22 | |
| Race | |||||||
| Other (8) vs. White (26) | 0.83 | 1.15 | 0.32, 4.09 | ||||
| Stage | IIB/III (4), IVA (4), IVB (26) | 0.87 | 0.62 | ||||
| IIB/III/IVA (8) vs. IVB (26) | 0.59 | 1.40 | 0.39, 4.99 | 1.93 | 0.51, 7.38 | ||
| Mesothelin expression | >50 (19) vs. <50 (15) | 0.003 | 4.46 | 1.55, 12.80 | 5.39 | 1.77, 16.40 | |
The reference group used to calculate the hazard ratio is indicated first.